NEXGEL Reports 31.5% Revenue Growth to $11.4M in 2025, Narrows Net Loss
NXGL is trading near its 52-week low of $0.577 (9.7% above the low) on light trading volume (0.2× avg).
Summary
NEXGEL reported its fiscal 2025 annual results via its 10-K filing, showing significant revenue growth and improved profitability metrics. The company achieved $11.4 million in revenue, a substantial 31.5% increase year-over-year, primarily driven by branded consumer product sales. While still reporting a net loss, it narrowed to $(0.38) per share from $(0.50) in the prior year, alongside an improved gross profit margin of 39.5%. This indicates progress in scaling operations and enhancing product mix, which is crucial for a small-cap company. Traders will be watching for continued revenue acceleration and further narrowing of losses as the company invests in new channels and product development.
At the time of this announcement, NXGL was trading at $0.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.8M. The 52-week trading range was $0.58 to $3.02. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.